Pharmacologic treatments for covid-19 patients
Favipiravir vs Tocilizumab
This comparison will not be updated. Last search date 14 Dec, 2022.
Hospitalized patients
Forest plots
(last update: 2021-08-17)
To access all information :
- click here for Hospitalized patients
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=106
Back to your research
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| NCT04310228 Zhao H, Biomed Pharmacother, 2020 Full text Commentary |
Public/non profit |
Favipiravir Tocilizumab Favipiravir |
Favipiravir+Tocilizumab Favipiravir+Tocilizumab Tocilizumab |
RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 4 centers in China | N=26 |
Some concerns Details |
|